Simona King - Apr 18, 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role
Chief Financial Officer
Signature
/s/ Edgar Cale, Attorney-in-Fact
Stock symbol
PASG
Transactions as of
Apr 18, 2023
Transactions value $
-$2,156
Form type
4
Date filed
4/20/2023, 04:28 PM
Previous filing
Apr 5, 2023
Next filing
Aug 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Options Exercise $0 +6.25K $0.00 6.25K Apr 18, 2023 Direct F1
transaction PASG Common Stock Sale -$2.16K -2.05K -50% $1.05 2.05K Apr 18, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Restricted Stock Units Options Exercise $0 -6.25K -25% $0.00 18.8K Apr 18, 2023 Common Stock 6.25K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3 1/4 of the RSUs vested on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.